在4月15日发布的最终草案指南中，NICE推荐地加瑞克（Degarelix）用于治疗特定类型的晚期激素依赖性前列腺癌。
前列腺癌是一种常见病症，在英格兰和威尔士每年有3.7万多人被确诊为前列腺癌。当原发性癌症从前列腺扩散到身体其它部位如骨骼时，称之为转移性前列腺癌。
NICE卫生技术评估中心主任Carole Longson教授评论该草案指南说：“地加瑞克是一种激素治疗药物，它为癌症已扩散到脊柱并显示脊髓压迫体征或症状的患者提供了显著的临床获益。我们很高兴能推荐地加瑞克作为这类患者人群的治疗选择。”
该草案指南目前正在征求顾问们的意见，他们有机会上诉。直到NICE发布最终指南。
NICE draft guidance recommends a treatment for prostate cancer
In final draft guidance published today (15 April, 2014), NICE has recommended degarelix (Firmagon, Ferring Pharmaceuticals), as an option for treating advanced hormone dependent prostate cancer in people with spinal me-tastases who present with signs or symptoms of spinal cord compression.
Prostate cancer is common - more than 37,000 men are diagnosed with prostate cancer every year in England and Wales. me-tastatic prostate cancer describes when the primary cancer has spread from the prostate to other parts of the body, such as the bone.
Commenting on the draft guidance, Professor Carole Longson, Director, Centre for Health Technology eva1uation, NICE said: "Degarelix is a hormone therapy drug that provides an imp0rtant benefit for people with cancer that has spread to the spine and presents with signs or symptoms of spinal cord compression. We are pleased to be able to recommend degarelix as a treatment option in this population."
The draft guidance is now with consultees, who have the opportunity to appeal against it. Until NICE issues final guidance, NHS bodies should make decisions locally on the funding of specific treatments.
Ends
For more information call the NICE press office on 0845 003 7782 or out of hours on 07775 583 813.
The draft guidance will be available at http://guidance.nice.org.uk/TAG/352from 15 April, 2014.
Degarelix has a UK marketing authorisation for the 'treatment of adult male patients with advanced hormone-dependent prostate cancer'.
The Committee concluded that degarelix was non-inferior to LHRH agonists in suppressing testosterone levels and it acknowledged that degarelix is beneficial for avoiding testosterone flare which is particularly imp0rtant in people with spinal me-tastases who present with signs or symptoms of spinal cord compression because of the known relationship between the testosterone flare when hormonal treatment starts and the risk of spinal cord compression.
People currently receiving treatment initiated within the NHS with degarelix that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.
The evidence considered by the committee indicated that degarelix is a cost-effective use of NHS resources for treating advanced hormone-dependent prostate cancer only in people with spinal me-tastases who present with signs or symptoms of spinal cord compression.
The drug does not meet the criteria to be considered under end-of-life.
ab0ut NICE
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. We develop guidance, standards and information on high-quality health and social care. We also advise on ways to promote healthy living and prevent ill health.
Our aim is to help practitioners deliver the best possible care and give people the most effective treatments, which are based on the most up-to-date evidence and provide value for money, in order to reduce inequalities and variation.
Our products and resources are produced for the NHS, local authorities, care providers, charities, and anyone who has a responsibility for commissioning or providing healthcare, public health or social care services.
免责声明：
本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。
如有侵权，请联系我们删除